According to Study Finds, one in three adults in the United States is obese, and 13% of the global adult population is significantly overweight.
Obesity-related cancers account for 40% of all cancers diagnosed by doctors in the United States each year, and this is because cancer-fighting immune cells are rendered “useless or neutralized” by obesity.
A team from the University of Maynooth in Ireland has found that the glucagon-like peptide “GLP-1” is a “golden” pharmacological approach to tackling obesity, pointing out that the treatment has also shown the ability to activate natural mechanisms of the human body to destroy cancer cells.
According to “Study Finds”, the study authors stated that “GLP-1” can restore the functions of cancer-fighting immune cells, noting that this issue occurs independently of the primary weight loss function of this drug.
“My team and I are very excited about these new findings regarding the effects of GLP-1 therapy in people with obesity, and its benefits extend to reducing cancer risk,” said Andrew E. Hogan, the study’s principal investigator.
Read the Latest World News Today on The Eastern Herald.
